Miller R G, Bryan W W, Dietz M A, Munsat T L, Petajan J H, Smith S A, Goodpasture J C
Department of Neurology, California Pacific Medical Center, San Francisco, USA.
Neurology. 1996 Nov;47(5):1329-31. doi: 10.1212/wnl.47.5.1329.
We examined the toxicity of both single and multiple subcutaneous injections of recombinant human ciliary neurotrophic factor (rhCNTF) in 72 patients with ALS, in doses ranging from 2 to 100 micrograms/kg. Adverse events were generally dose related and ranged from mild to severe. The tolerability of daily subcutaneous rhCNTF was equivalent to placebo at doses < or = 5 micrograms/kg/day. At higher doses, anorexia, weight loss, reactivation of herpes simplex virus (HSV1) labialis/stomatitis, cough, and increased oral secretions occurred.
我们对72例肌萎缩侧索硬化症（ALS）患者皮下注射单剂量及多剂量重组人睫状神经营养因子（rhCNTF）的毒性进行了研究，剂量范围为2至100微克/千克。不良事件一般与剂量相关，程度从轻度到重度不等。每日皮下注射rhCNTF，剂量≤5微克/千克/天时，其耐受性与安慰剂相当。在更高剂量时，出现了厌食、体重减轻、唇/口腔单纯疱疹病毒1型（HSV1）复发/口腔炎、咳嗽和口腔分泌物增多等情况。
